Menssana research at NJIT receives kudos for FDA-approved breath test

November 22, 2004

In a fifth-floor laboratory at New Jersey Institute of Technology (NJIT), research assistant Renee Cataneo is holding the day's collection of human exhalations sent to Menssana Research, based at NJIT. Cataneo's job is to analyze the results. Just as a Breathalyzer detects drunk drivers, a Menssana process detects illness.

"It's the same concept, but about a billion times more sensitive," said inventor Michael Phillips, MD, a clinical professor of medicine at New York Medical College, Valhalla, NY. Since December 2002, Menssana Research has been a tenant in the Enterprise Development Center, an incubator program at NJIT for young businesses.

A week ago, the Wall Street Journal named Menssana Research in its annual technology innovation awards as the second runner-up for kudos in the biotechnology and medical section. (EDITORS NOTE: To interview Phillips either in his lab or by telephone, contact Sheryl Weinstein at 973-596-3436.)

In a patented process, samples are imbedded in activated carbon, sealed in cigarette-sized steel cylinders and then mailed to the lab for analysis. Menssana has identified distinct patterns made by more than 200 different volatile organic compounds exhaled in every breath. Phillips has proved that these patterns vary with illness and can be used to diagnose a variety of diseases.

"It's more than folk medicine," said Phillips. "Diabetics' breath smells fruity because of acetones, patients in kidney failure have breath that smells like urine, and liver disease and lung infections also have distinctive odors." But Phillips' research has taken breath analysis way beyond the sniff test.

In February 2004, the federal Food and Drug Administration approved the marketing of Menssana's Heartsbreath test. The test determines whether patients with heart transplants are showing signs of rejecting the new heart. The FDA said the test might be used as an adjunct to biopsy. The Heartsbreath test costs $500, compared to thousands for a biopsy. More importantly, it is non-invasive and has no risks.

Phillips has also published research in peer-reviewed journals-including the prestigious medical journal, Chest-showing that the breath-test concept works to diagnose lung cancer, breast cancer, tuberculosis, and pre-eclampsia, a precursor of a life-threatening complication of pregnancy.

The principle behind his research is a bodily process called "oxidative stress." That means that disease is associated with an increase in "free radicals," molecules whose unpaired electrons make them highly reactive. Those free radicals damage the cell membrane, releasing the volatile organic compounds some of which ultimately are exhaled. Phillips came up with a way to use activated charcoal to capture these compounds, concentrate them with intense heat, and then use a gas chromatograph to separate the compounds and a mass spectrometer to identify them. The resulting graph will show a distinctive pattern that can determine health or illness, Phillips said. The inventor also believes the breath analysis concept could screen for an almost limitless array of diseases. One of his tasks is deciding which ones to go after. "It's completely safe, has virtually no false negative results, and it's cheap," he said.
-end-
New Jersey Institute of Technology, the state's public technological research university, enrolls more than 8,800 students in bachelor's, master's and doctoral degrees in 100 degree programs offered by six colleges: Newark College of Engineering, New Jersey School of Architecture, College of Science and Liberal Arts, School of Management, Albert Dorman Honors College and College of Computing Sciences. NJIT is renowned for expertise in architecture, applied mathematics, wireless communications and networking, solar physics, advanced engineered particulate materials, nanotechnology, neural engineering and eLearning.

New Jersey Institute of Technology

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.